Paragon Biomedical
Paragon Biomedical is recorded as a service provider in 1 clinical trial. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 1 of 1 trials · Latest update first
A Phase 1, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 as Monotherapy in Patients with Selected Advanced Solid Tumors
Sponsor ADC Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available4 trial-level findings · Read insights
- Enrollment was substantially below plan: 30 patients were enrolled globally versus approximately 132 planned.
- Part 1 enrolled 26 of 92 planned patients and Part 2 enrolled 4 of 40 planned patients; backfilling was not opened.
- The study operated at 13 sites: 4 in Spain, 2 in the United Kingdom, and 7 in the United States.
- Following the single response observed in cholangiocarcinoma during Part 1, Part 2 enrolled only patients with cholangiocarcinoma; no response was observed in Part 2.
These findings describe the trial, not the service provider’s performance or responsibility.
Questions about this trial experience
What services are recorded for Paragon Biomedical?
The 2026-10-09 snapshot links Paragon Biomedical to 1 distinct CTIS trials. Recorded services include Clinical monitoring, Project management, Regulatory and Ethics submissions. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Paragon Biomedical?
The most frequently recorded therapeutic areas are Gynecology, Hepatology, Solid Tumor Oncology, Urology. Study-phase tags are not recorded. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Paragon Biomedical conducted?
The linked trials record locations in 1 country, including Spain. These are trial locations, not confirmed office locations or countries where Paragon Biomedical delivered services.
What can this page tell me about Paragon Biomedical's trial experience?
Browse 1 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Paragon Biomedical. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Paragon Biomedical Limited